• 1
    Garg S, Serruys PW. Coronary stents: current status. J Am CollCardiol. 2010;56:S1S42.
  • 2
    Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009;23:8592.
  • 3
    Morrow DA, Cannon CP, Jesse RL, et al; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356e375.
  • 4
    Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am CollCardiol. 2006;48:111.
  • 5
    Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109:III15III19.
  • 6
    Girndt M, Kohler H. Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrol Dial Transplant. 2003; 18:19761979.
  • 7
    Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190195.
  • 8
    Jones GT, van Rij AM, Cole J, et al. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem. 2007;53:679685.
  • 9
    Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46:19561967.
  • 10
    Delhaye C, Maluenda G, Wakabayashi K, et al. Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. Am J Cardiol. 2010;105:826832.
  • 11
    Iijima R, Byrne RA, Ndrepepa G, et al. Pre-proceduralC-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart 2009;95:107112.
  • 12
    Razzouk L, Muntner P, Bansilal S, et al. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J. 2009;158:277283.
  • 13
    Gach O, Legrand V, Biessaux Y, et al. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol. 2007;99:3135.
  • 14
    Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:28442853.
  • 15
    Alaigh P, Hoffman CJ, Korlipara G, et al. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. ArteriosclerThrombVasc Biol. 1998;18:12811286.
  • 16
    Cooke T, Sheahan R, Foley D, et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation. 1994;89:15931598.
  • 17
    Desmarais RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91:14031409.
  • 18
    Gazzaruso C, Garzaniti A, Falcone C, et al. Restenosis after intracoronary stent placement: can apolipoprotein(a) polymorphism play a role? Int J Cardiol. 2003;87:9198.
  • 19
    Miyata M, Biro S, Arima S, et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J. 1996;132:269273.
  • 20
    Ribichini F, Steffenino G, Dellavalle A, et al. Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation. 1998;98:11721177.
  • 21
    Wehinger A, Kastrati A, Elezi S, et al. Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. J Am CollCardiol. 1999;33:10051012.
  • 22
    Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am CollCardiol.2002;40: 13751382.
  • 23
    Igarashi Y, Aizawa Y, Satoh T, et al. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein (a). Circ J. 2003;67:605611.
  • 24
    Rahel BM, Visseren FL, Suttorp MJ, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003;60: 136140.
  • 25
    Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17e24.
  • 26
    Oemrawsingh RM, Lenderink T, Akkerhuis KM, et al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart. 2011;97:10611066.
  • 27
    Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J. 2002;144:811817.
  • 28
    Chang LT, Yuen CM, Sun CK, et al. Role of stromal cell-derived factor-1alpha, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 2009;73:10971104.
  • 29
    Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:21092114.
  • 30
    Yip HK, Youssef AA, Chang LT, et al. Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Circ J. 2007;71:10861091.
  • 31
    Ezhov MV, Sumarokov AB, RaimbekovaIR, Masenko VP, Naumov VG. Interleukin 6 but not interleukin 10 is associated with restenosis after coronary stenting. Atherosclerosis. 2003;169:193194.
  • 32
    Zurakowski A, Wojakowski W, Dzielski T, et al. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting. Kardiol Pol. 2009;67:623630.